Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $109.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality.
Protagonist Therapeutics is a clinical-stage peptide biopharma with two lead programs licensed to major pharma: icotrokinra (Icotyde, IL-23R antagonist for psoriasis) partnered with J&J/Janssen (NDA filed July 2025) and rusfertide (hepcidin mimetic for polycythemia vera)... Read more
Sell if holding. Engine safety override at $109.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Protagonist Therapeutics, Inc.
Latest news
- NEWS Why Did Protagonist Therapeutics Stock Soar Today? - MSN — MSN positive
- NEWS Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com — Investing.com positive
- NEWS Protagonist Therapeutics: Q1 Earnings Snapshot - KING5.com — KING5.com neutral
- NEWS Protagonist Therapeutics: Q1 Earnings Snapshot - wwltv.com — wwltv.com neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineIcotyde and rusfertide10-K Item 1A: 'Our future success is substantially dependent on our ability and the ability of our collaborators to timely complete clinical trials and obtain marketing approval for... our clinical-stage product candidates, such as Icotyde and rusfertide.'
- HIGHcounterpartyJNJ and Takeda10-K Item 1A: 'If JNJ does not elect to continue the development of or successfully commercialize Icotyde, or if Takeda does not elect to commercialize rusfertide, our business and business prospects would be adversely affected.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $109.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Prior stop was $102.10. Score 5.3/10, moderate confidence.
Take-profit target: $109.22 (-0.5% upside). Prior stop was $102.10. Stop-loss: $102.10.
Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ and Takeda; Target reached (-5.9% upside).
Protagonist Therapeutics, Inc. trades at a P/E of N/A (forward -154.5). TrendMatrix value score: 4.0/10. Verdict: Sell.
20 analysts cover PTGX with a consensus score of 4.3/5. Average price target: $119.
What does Protagonist Therapeutics, Inc. do?Protagonist Therapeutics is a clinical-stage peptide biopharma with two lead programs licensed to major pharma:...
Protagonist Therapeutics is a clinical-stage peptide biopharma with two lead programs licensed to major pharma: icotrokinra (Icotyde, IL-23R antagonist for psoriasis) partnered with J&J/Janssen (NDA filed July 2025) and rusfertide (hepcidin mimetic for polycythemia vera) partnered with Takeda (NDA filed December 2025). The company holds $646M in cash and is eligible for up to $1.6B in combined milestones from both collaborations.